Neither plasma coenzyme Q₁₀ concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: A prospective case–control study from the

详细信息    查看全文

• 作者：Roland Stocker ; Christine Pollicino ; Craig A. Gay ; Paul Nestel ; David Colquhoun ; Malcolm Whiting ; Andrew Tonkin ; David Sullivan and John Simes
• 关键词：Antioxidants ; 3-Hydroxy-3-methylglutaryl coenzyme A reductase ; Statin ; n-6 Polyunsaturated fatty acids
• 刊名：Atherosclerosis
• 出版年：2006
• 出版时间：July 2006
• 年：2006
• 卷：187
• 期：1
• 页码：198-204
• 全文大小：127 K

文摘

Statins decrease LDL cholesterol and the risk of atherosclerotic cardiovascular disease (CVD). They also decrease coenzyme Q₁₀ (CoQ₁₀), an effect that may negate some of the statin benefit on CVD. We examined the relationship between plasma CoQ₁₀ concentration and CVD in a prospective case–control study of the effect of pravastatin. Plasma samples from 250 LIPID trial patients who over 6 years suffered a recurrent CVD event (CVD death, nonfatal MI or stroke) and 250 matched controls who remained event-free for the same duration of follow-up were assayed for CoQ₁₀ and lipids (cholesterol and cholesterylesters). Mean plasma CoQ₁₀ concentrations were significantly lower in pravastatin-treated patients than in those assigned placebo (0.51 versus 0.60 μmol/L, P = 0.006), and there was a moderate correlation between CoQ₁₀ and common cholesterylesters (Pearson correlation coefficients in patients randomised to placebo, range r = 0.42–0.63). Univariate conditional logistic regression did not suggest any relationship between plasma CoQ₁₀ and the risk of future CVD events (odds ratio 1.18; 95 % CI 0.74–1.87; P = 0.49). Instead, we observed a reduction in the rate of recurrent CVD events with increasing ratio of plasma cholesterylarachidonate to cholesteryllinoleate. This study confirms that pravastatin lowers plasma CoQ₁₀ concentrations, but this does not appear to predict the risk of recurrent CVD events.